Venus Remedies
- Market cap
- ₹ 1,907 Cr.
- P/E
- 14.6x
- P/B
- 2.9x
- 52-week range
- 432.1 – 2,044.3
- ROE
- 17%
- ROCE
- 22%
- Dividend yield
- 0.7%
- Debt / equity
- 0.02
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
Venus Remedies Limited is a research-driven pharmaceutical company. The Company is a global injectable manufacturer. It manufactures products catering to critical care segments such as antimicrobial resistance, anti-cancer, Anti-infective, Neurology, Skin and Wound Care, and Pain Management. With a diverse portfolio of products, the Company is dedicated to revolutionizing patient care through its specialized therapeutic segments such as anti-infective (antibiotics), oncology, neurology, pain management, and skin & wound care. The Company operates only in one business segment: Pharmaceutical Formulation and is engaged in manufacturing and trading of medicines. Its focus therapy areas include medicine, surgery, neuro and orthopedics. The Company’s brands include Potentox, Vancoplus Combi, Tobracef, Supime, Zydotum, Neurotol, Trois, Septiloc, Mucomelt, and others. It has three manufacturing facilities: Panchkula and Baddi in India and Werne in Germany.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →Venus Remedies against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)14.6 against a typical 34.3: cheaper than most peers (1st = cheapest).37th of 220
- Sales growth+30.7% against a typical +15.6% from a year earlier.56th of 197
- Profit growth+130% against a typical +18.9% from a year earlier.23rd of 160
- Share price, 3 months+12.6% against a typical −0.5%.54th of 200
- Size₹ 1,906.9 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).74th of 199
Latest announcements
Exchange filings and their impact on the company.
- 26 Oct 2026Outcome of Board MeetingHigh impactPositiveStrong Q2/H1 FY27 with 20% revenue and 64% profit growth signals sustained earnings momentum.
Venus Remedies reported strong Q2 FY27 results with consolidated revenue of Rs 218.76 crore, up 13.5% year-on-year, and net profit of Rs 25.65 crore, up 27.4%. For H1 FY27, revenue was Rs 397.62 crore and net profit Rs 48.62 crore, up 20.5% and 63.5% respectively. Growth was partly offset by a Rs 5.84 crore loss in German subsidiary Venus Pharma GmbH and Rs 2.77 crore extra amortisation, with auditors flagging Rs 28.6 crore pending share application money in the subsidiary under restructuring.
- 16 Oct 2026UpdatesLow impactPositiveVenus wins five drug approvals across four countries to support export growth.
Venus Remedies has secured five marketing authorisations across Kazakhstan, Peru, Kuwait and Argentina for Vancomycin, Fluorouracil, Fulvestrant, Methotrexate and Meropenem. The approvals span the CIS region, Latin America and the Middle East and expand its critical-care injectables portfolio. The company, already present in over 100 countries, expects this to support sustainable international growth as the products are commercialised.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 26 Oct 2026 | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 20 Jul 2026 | Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2026 and other business matters |
| 26 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026, dividend and Agenda pertaining to ensuing Annual General Meeting of the company. |
| 29 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 and any other item with the permission of chair. |
| 19 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 and any other item with the permission of chair. |
| 10 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 | 180 | 259 | 179 |
| Expenses | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 | 143 | 196 | 145 |
| Operating Profit | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 | 38 | 63 | 34 |
| OPM % | 11% | 8% | 10% | 10% | 4.5% | 10% | 15% | 11% | 16% | 21% | 24% | 19% |
| Other Income | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 | 3 | 5 | 3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 | 7 | 7 | 7 |
| Profit before tax | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 | 33 | 62 | 30 |
| Tax % | 31% | 12% | 40% | 82% | 61% | 21% | 32% | 24% | 24% | 24% | 23% | 24% |
| Net Profit | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 | 26 | 48 | 23 |
| EPS in Rs | 7.44 | 5.12 | 7.86 | 0.91 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 | 19.14 | 35.54 | 17.18 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 7%
- 5 Years
- 7%
- 3 Years
- 12%
- TTM
- 20%
- 10 Years
- 51%
- 5 Years
- 22%
- 3 Years
- 57%
- TTM
- 149%
- 10 Years
- 35%
- 5 Years
- 28%
- 3 Years
- 96%
- TTM
- —
- 10 Years
- 5%
- 5 Years
- 10%
- 3 Years
- 10%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Venus Remedies | ₹ 1,805.00 | ₹ 1,907 Cr. | 14.6x | 2.9x | 17% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Pawan Chaudhary
- Chairman of the Board, Chief Financial Officer, Managing Director
- Neha Kodan
- Compliance Officer, Company Secretary
- Manu Chaudhary
- Joint Managing Director, Whole Time Director
- Peeyush Jain
- Deputy Managing Director, Whole-Time Director
- Akshansh Chaudhary
- Additional Whole Time Director
- Saransh Chaudhary
- Additional Whole Time Director
- Ashutosh Jain
- Whole-time Executive Director
Prices are delayed and for information only. Nothing on this page is investment advice.